Pimecrolimus in dermatology

Giornale Italiano di Dermatologia e Venereologia

Volumn 144, Issue 3, 2009, Pages 321-325

  Fabroni, C ^a,b   Lotti, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NONE   (Italy)

Author keywords

Dermatitis, atopic; Lupus erithematosus, cutaneous; Pimecrolimus; Psoriasis; Skin diseases; Vitiligo

Indexed keywords

ANTIHISTAMINIC AGENT; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; GLUCOCORTICOID; PIMECROLIMUS; TACROLIMUS;

ACNE; AGED; APPLICATION SITE PAIN; APPLICATION SITE REACTION; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; DERMATOLOGY; DRUG ABSORPTION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LICHEN SCLEROSUS ET ATROPHICUS; LUPUS ERYTHEMATOSUS; NONHUMAN; PAIN; PERIORAL DERMATITIS; PRESCRIPTION; PSORIASIS; SCLERODERMA; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN MANIFESTATION; STRIA; UNSPECIFIED SIDE EFFECT; VITILIGO;

EID: 68849129427     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Exp Opin Investig Drugs 2000;9:69-77. (Pubitemid 30011549)
2. Grassberger M, Baumruker T, EnzA, Hiestand P, Hultsch T, Kalthoff F et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin disease: in vitro pharmacology. Br J Dermatol 1999;141:263-273 (Pubitemid 29397994)
3. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003;17:493-503.
4. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZASM 981)-preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001,20:233-241 (Pubitemid 33139090)
5. Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs 2000;9:69-77 (Pubitemid 30011549)
6. Luger T, Van Leent EJM, Graeber M, Hedgecock S, Thurston M, Kandra A et al. SDZ ASM 981: an emerging safe and effective treatment of atopic dermatitis. Br J Dermatol 2001;144:788-794 (Pubitemid 32374782)
7. Greig G, Burtin P, Wolff K. Oral SDZASM 981: Clinical safety, tolerability, and efficacy in patients with moderate to severe chronic plaque psoriasis. Proceedings of the American Academy of Dermatology Annual Meeting; 2001 Mar 2-7; Washington, DC, USA. Schaumburg, IL: American Academy of Dermatology; 2001.
8. Bos JD. Non steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur J Dermatol 2003;13:455-461
9. Harper J, Lakhanpaul M, Wahn U et al. Pimecrolimus (SDZ ASM 981) blood levels are consistently low in children with extensive atopic eczema. Proceedings of the 10th Congress of the European Academy of Dermatology and Venereology (EADV); 2001 October 10-14; Munich, Germany. Acta Dermatovenerol Alp Panonica Adriat 2001;10.
10. Berger TG, Duvic M, Van VoorheesAS, VanBeek MJ, Frieden IJ; the American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. J Am Acad Dermatol 2006;54:818-823
11. Sancez-Perez J. Topical pimecrolimus and tacrolimus and risck of cancer. Actas Dermosifilogr 2007;98:312-317 (Pubitemid 47013028)
12. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inihibitors decrease DNA repairs and apoptosisin human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005;125:1020-1025
13. Buggiani G, Ricceri F, Lotti T. Atopic dermatitis. Dermatol Ther 2008;21:96-100.
14. Williams HC. Clinical practice. Atopie dermatitis. N Engl J Med 2005;352:2314-2324
15. Wahn U, Bos JD, Goodfield M, Caputo R, PappK, Manjra A et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110(1pt1):e2.
16. Thaci D, Salgo R. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update. Acta Dermatoven 2007;16:58-62. (Pubitemid 47020362)
17. Lotti T, Gori A, Zanieri F, Colucci R, Moretti S. Vitiligo: new and emerging treatments. Dermatol Ther 2008;21:110-117
18. Hercogová J, Buggiani G, Prignano F, Lotti T. A rational approach to the treatment of vitiligo and other hypomelanoses. Dermatol Clin 2007;25:383-392 (Pubitemid 47088894)
19. Lotti T, Buggiani G, Troiano M, Assad GB, Delescluse J, De Giorgi V et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther 2008;21(Suppl 1):S20-6.
20. Forschner T, Buchholtz S, Stockfleth E. Current state of vitiligo therapy - evidence-based analysis of the literature. J Dtsch Dermatol Ges 2007;6:467-475 (Pubitemid 46917313)
21. Wollina U, Hansel G, Koch A, Abdel-Naser MB. Topical pimecrolimus for skin disease other than atopic dermatitis. Exp Opin Pharmacother 2006;7:1967-1975 (Pubitemid 44489369)
22. Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ et al. Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2008;60,1:120-4.
23. Bigby M. Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis. Arch Dermatol 2005;141:1152-1153
24. Wollina U, Hansel G. Topical calcineurin inhibitors in cutaneous Lupus. J Eur Acad Dermatol Venereol 2008;22:1-6.
25. Schürmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag 2006; 2:213-218 (Pubitemid 43950058)
26. Oskay T, Sezer HK, Genç C, Kutluay L. Pimecrolimus 1% cream in the treatment of vulvar lichen sclerosus in postmenopausal women. Int J Dermatol 2007,46:527-532 (Pubitemid 46711440)
27. Volz T, Caroli U, Ludtke H, Bräutigam M, Kohler-Späth H, Röcken M et al. Pimecrolimus cream 1% in erosive oral lichen planus-a prospective randomized double-blind vehicle-controlled study. Br J Dermatol 2008;59:936-941